US 2020/0246423 Al  80  Aug. 6, 2020  TABLE 85  TABLE 86-continued  TABLE 87  TABLE 86  [0434]  The aflibercept concentration (mg/mL), pH, and  osmolality (mOSm) of the Block G formulations were  evaluated at  tO.  Results are reported in Table 87 below.  Concentration, pH, and Osmolality  [0433]  This example describes experiments to evaluate  aflibercept formulations with various excipient combina› tions (Block G). Formulations in Block G include those that  are free of a buffer; free of an organic co-solvent; include a  sugar other than sucrose, include a polyol; include a surfac› tant other than polysorbate 20 (e.g. in buffer-free formula› tions); include CaC1$_{2 }$ as a stabilizer; and have a high con› centration of aflibercept.  Table  86,  below,  shows  an  exemplary set of such formulations.  [0432]  The aflibercept formulations of Block F are physi› cally and chemically stable.  Discussion  Example 8-Aflibercept Formulations  ic!EF results for Block F formulations after storage for four weeks at 5°  C.  Rel. Area (%) Smoothing (Grou12)  Formulation Block  2  3  4  5  6  7  8  9  F-1  3.7 6.2 7.4  11.8  14.3  15.4  14.1  11.4  7.8  F-2  4.8 5.9 7.8  11.5  14.6  14.6  14.1  11.5  7.8  F-3  4.3 6.1  7.2  12.5  14.3  14.5  14.1  11.9  7.6  F-4  4.6 6.0 7.9  12.5  13.5  15.0  14.0  11.4  7.8  F-5  4.5 6.3  7.6  11.5  14.7  15.0  13.7  11.4  7.8  F-6  4.6 6.1  7.5  11.8  14.5  15.2  13.8  11.3  7.9  F-7  4.5 6.1  7.7  11.7  14.1  15.1  13.9  11.8  7.6  F-8  4.4 6.6 7.4  11.6  14.2  15.7  13.7  11.2  7.9  F-9  4.1  6.5  7.6  11.9  14.0  15.2  14.1  11.3  7.8  F-10  4.3 6.3  7.5  12.2  13.6  15.3  14.0  11.2  8.3  F-11  4.4 7.2 6.4  12.3  13.8  15.5  14.2  11.5  7.7  F-12  4.5 6.7 6.9  12.3  14.3  14.7  14.0  11.7  7.4  F-13  4.2 6.8 7.0  12.7  14.0  14.9  14.3  11.1  8.1  F-14  4.5 6.2 7.2  11.9  14.5  14.6  14.0  11.5  7.8  F-15  4.6 6.2 7.3  11.6  14.7  14.6  13.5  11.7  7.9  10  11  4.8 2.3  4.8 2.1  4.8 2.1  4.7 2.1  4.8 2.2  4.6 2.1  4.9 2.1  4.5 2.0  4.8 2.1  4.8 2.0  4.7 1.8  4.7 2.3  4.5 1.9  4.7 2.3  4.6 2.3  12  0.8  0.6  0.6  0.5  0.6  0.6  0.5  0.6  0.6  0.6  0.6  0.6  0.5  0.8  0.8  Form  No.  G-18  G-19  G-20  G-21  G-22  G-23  G-24  Sucrose NaCl  aflibercept  pH  (mM)  (mM)  40 mg/ml  6.2  270  40 mg/ml  6.2  200  40 mg/ml  6.2  200  40 mg/ml  6.2  170  40 mg/ml  6.2  200  40 mg/ml  6.2  200  40 mg/ml  6.2  200  0  40  40  40  0  20  20  Surfactant  (wt%)  0.06% PS 80  0  0  0  0  0  0.03% PS 20  Other  None  !%PG  1% glycerol  5% glycerol  20mM  glycine  l0mM  CaC1$_{2 }$ l0mM  CaC1$_{2 }$ Form  No.  aflibercept  G-1  40 mg/ml  G-2  80 mg/ml  G-3  120 mg/ml  G-4  40 mg/ml  G-5  80 mg/ml  G-6  120 mg/ml  G-7  40 mg/ml  G-8  40 mg/ml  G-9  40 mg/ml  G-10  40 mg/ml  G-11  40 mg/ml  G-12  40 mg/ml  G-13  40 mg/ml  G-14  40 mg/ml  G-15  40 mg/ml  G-16  40 mg/ml  G-17  40 mg/ml  Sucrose NaCl  pH  (mM)  (mM)  Surfactant  (wt%)  6.2  200  40  0  6.2  200  40  0  6.2  200  40  0  6.2  200  40  0.03% PS 20  6.2  200  40  0.03% PS 20  6.2  200  40  0.03% PS 20  6.2  200  40  0.06% PS 20  6.2  200  40  0.03% PS 80  6.2  200  40  0.06% PS 80  6.2  200  40  0.1% F-68  6.2  0  40  0  6.2  0  40  0  6.2  0  40  0  6.2  0  40  0  6.2  0  40  0  6.2  170  40  0  6.2  170  40  0  Other  l0mM  His  l0mM  His  l0mM  His  None  None  None  None  None  None  None  200 mM  trehalose  200 mM  lactose  200 mM  sorbitol  200 mM  glycine  200 mM  xylitol  50mM  phosphate  50mM  His  Final Concentration  Final  Final Osmolality  Form  No.  (mg/mL)  pH  (mOsm/Kg)  G-1  78.13  6.23  354  G-2  117.44  6.26  360  G-3  40.02  6.24  300  G-4  78.55  6.23  330  G-5  118.49  6.23  361  G-6  39.63  6.22  298  G-7  39.27  6.22  298  G-8  39.83  6.21  293  G-9  39.71  6.21  300  G-10  39.70  6.28  332  G-11  38.97  6.22  320  G-12  39.56  6.27  296  G-13  40.39  6.24  286  G-14  39.47  6.18  298  G-15  39.73  6.26  377  G-16  39.63  6.23  354  G-17  38.65  6.24  313  G-18  39.59  6.28  467  G-19  39.76  6.25  436  G-20  39.52  6.21  945 